Plaas Mihkel, Brazovskaja Agnieska, Kisand Kai, Tserel Liina, Peterson Pärt
Ear Clinic Tartu University Hospital Tartu Estonia.
Institute of Clinical Medicine University of Tartu Tartu Estonia.
Clin Case Rep. 2024 Dec 9;12(12):e9692. doi: 10.1002/ccr3.9692. eCollection 2024 Dec.
We identified two CRSwNP patients who had previously failed treatment with an anti-IL-4/IL-13 antibody (dupilumab). Based on their clinical characteristics and blood cytokine levels, we considered them mixed Type II/Type III cases and treated them with an anti-IL-17 antibody (secukinumab). Anti-IL-17 antibody secukinumab was superior in reducing their NPS and SNOT-22 values compared to dupilumab. IL-17 could be a promising target for non-type II and mixed endotype CRS treatment.
我们识别出两名先前使用抗IL-4/IL-13抗体（度普利尤单抗）治疗失败的慢性鼻-鼻窦炎伴鼻息肉（CRSwNP）患者。根据他们的临床特征和血液细胞因子水平，我们认为他们属于II型/III型混合病例，并使用抗IL-17抗体（司库奇尤单抗）对他们进行治疗。与度普利尤单抗相比，抗IL-17抗体司库奇尤单抗在降低他们的鼻息肉评分（NPS）和鼻窦症状测试-22（SNOT-22）值方面更具优势。IL-17可能是治疗非II型和混合型内型CRS的一个有前景的靶点。
